Results 21 to 30 of about 341,590 (292)
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy
Arthritis & Rheumatology, 2023 This open‐label, 24‐week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (DM).
R. Curiel +10 more
semanticscholar +1 more source
Pediatric Rheumatology Online Journal, 2023 Background We lack a reliable indicator of disease activity in Juvenile Dermatomyositis (JDM), a rare disease. The goal of this study is to identify the association of nailfold capillary End Row Loop (ERL) loss with disease damage in children with newly ...
L. Pachman +4 more
semanticscholar +1 more source
The von Willebrand Factor Antigen Reflects the Juvenile Dermatomyositis Disease Activity Score
Biomedicines, 2023 Objective: This study determined if an accessible, serologic indicator of vascular disease activity, the von Willebrand factor antigen (vWF:Ag), was useful to assess disease activity in children with juvenile dermatomyositis (JDM), a rare disease, but ...
Ellie Gibbs +4 more
semanticscholar +1 more source
B Cell Lymphocytosis in Juvenile Dermatomyositis
Diagnostics, 2023 In this study, we determined if B lymphocytosis may serve as a JDM biomarker for disease activity. Children with untreated JDM were divided into two groups based on age-adjusted B cell percentage (determined through flow cytometry): 90 JDM in the normal ...
Christopher Costin +7 more
semanticscholar +1 more source
Juvenile dermatomyositis. Where are we now?
Clinical and Experimental Rheumatology, 2022 Juvenile onset idiopathic inflammatory myopathy (IIM) has many similarities and distinct differences from adult-onset disease. This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common
L. McCann +3 more
semanticscholar +1 more source
Ugeskrift for Læger, 2023 Juvenile dermatomyositis (JDM) is a rare condition, which causes inflammation in children’s skin and musculoskeletal systems. Symptoms include characteristic skin rashes on the face and extremities, muscle pain and weakness. This is a case report of a ten-year-old boy initially suspected of having lupus erythematosus. He was later diagnosed with JDM by
Vigand Svendsen, Sebastian +3 more
openaire +2 more sources
Frontiers in Pediatrics, 2022 Objective To determine the short-term effectiveness safety of baricitinib in children with refractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting. Methods This was a single-center retrospective study, including 20 children with
Zhaoling Wang +8 more
semanticscholar +1 more source
Annals of the Rheumatic Diseases, 2022 Objectives To define the host mechanisms contributing to the pathological interferon (IFN) type 1 signature in Juvenile dermatomyositis (JDM). Methods RNA-sequencing was performed on CD4+, CD8+, CD14+ and CD19+ cells sorted from pretreatment and on ...
M. Wilkinson +14 more
semanticscholar +1 more source
Rheumatology, 2021 OBJECTIVE To evaluate the efficacy and safety of JAK inhibitors (JAKi) in juvenile dermatomyositis (JDM). METHODS We conducted a single-center retrospective study of patients with JDM treated by JAKi with a follow-up of at least 6 months. Proportion of
Tom Le Voyer +14 more
semanticscholar +1 more source
Journal of Medical Case Reports, 2021 Background Juvenile dermatomyositis is an inflammatory disease of muscles, skin, and blood vessels of unknown cause affecting all age and ethnic groups, with a reported incidence of 1.9–4.1 per million.
Fatima Mussa +2 more
doaj +1 more source